Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd.

April 12, 2007 12:51 ET

Urodynamix Expands NIRS Intra-Abdominal Pressure Study

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 12, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) announced that it has received notification from Health Canada allowing the Company to expand its clinical trial ("NIRS IAP Study") at the Foothills Medical Centre in Calgary, Alberta. Under the approved protocol the Company may enroll up to 70 intensive care unit ("ICU") patients and will monitor subjects continuously for up to 7 days.

Based on the success of the Company's initial NIRS IAP clinical trial, the Company and the investigators sought approval to increase the monitoring period from 24 hours to up to 7 days in order to test the device in an environment that more accurately reflects the clinical ICU setting. According to data on inpatient admissions processed for the Centers for Medicare and Medicaid Services, patients at short-term acute care hospitals who require admission to an ICU have an average length of stay of 8 days. However, elevated intra-abdominal pressure ("IAP") is associated with severe organ dysfunction during the ICU stay, and a recent study showed significantly longer average ICU stays of up to 28 days among abdominal compartment syndrome ("ACS") patients who suffer multiple organ dysfunction due to sustained elevated IAP.

The goal of the NIRS IAP Study is to evaluate the Company's prototype near-infrared spectroscopy ("NIRS") device for continuous monitoring of changes in IAP in critical care ICU patients compared to intermittent catheter-based IAP measurements. Untreated ACS is fatal, and recent studies have confirmed the importance of early intervention and treatment in these patients.

Urodynamix believes that its NIRS technology may be used to continually and non-invasively monitor physiological changes corresponding to elevated IAP and abdominal tissue ischemia. Preliminary data from 10 ICU patients at Foothills Medical Centre confirmed that NIRS measurements of the abdominal wall correlated with IAP in the ICU patients studied (see news release dated January 17, 2007 for details).

The occurrence of elevated IAP during the ICU stay is an independent risk factor for mortality, and it is estimated that 30-50% of all ICU patients develop IAP and that up to one in eleven may develop ACS. Despite increased recognition and improved treatment, the overall mortality rate of ACS remains over 50%. Continuous IAP monitoring may allow clinicians to detect the onset of ACS earlier and intervene before clinical signs develop, resulting in significant cost savings and improved patient outcomes.

About Urodynamix Technologies Ltd.

Urodynamix is developing a portfolio of non-invasive diagnostic products for a variety of large and growing global markets. The Company is currently developing NIRS applications for urinary incontinence in men and women, intra-abdominal hypertension and compartment syndrome, erectile dysfunction and vascular diseases. The Company's disruptive technology has the potential to affect the diagnosis and treatment of more than 200 million people worldwide.

On behalf of the Board,

Barry Allen, President & CEO

Urodynamix Technologies Ltd.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information